Atea Pharmaceuticals (AVIR) said Wednesday that the first patient has been dosed in its late-stage trial comparing the combination regimen of bemnifosbuvir and ruzasvir with the combination regimen of sofosbuvir and velpatasvir for the treatment of chronic hepatitis C virus.
The bemnifosbuvir and ruzasvir regimen will be administered orally once a day for eight weeks in patients without cirrhosis or 12 weeks in patients with compensated cirrhosis, while the sofosbuvir and velpatasvir regimen will be administered orally once a day for 12 weeks, the company said.
The company said infection with chronic hepatitis C virus is the leading cause of liver cancer in the US, Europe and Japan.
Shares of Atea Pharmaceuticals were down more than 30% in recent premarket activity Wednesday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.